Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00440050 · ClinicalTrials.gov registry record · Phase 3
DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease
A Phase 3 study, sponsored by Alzheimer's Disease Cooperative Study (ADCS).
- Completed
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
NCT00440050 is a Phase 3 study that has completed, run by Alzheimer's Disease Cooperative Study (ADCS). The registered enrollment target is 402 participants.
The verdict
NCT00440050, a Phase 3 study, has completed, sponsored by Alzheimer's Disease Cooperative Study (ADCS).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).
Interventions
- DRUG Placebo
- DRUG DHA (Docosahexaenoic Acid)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00440050
The ClinicalTrials.gov registry entry for NCT00440050 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alzheimer's Disease Cooperative Study (ADCS), which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00440050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00440050 about?
NCT00440050 is a clinical study titled "DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease". The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).
What is the current status of trial NCT00440050?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2007-02. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00440050?
The interventions under investigation include: Placebo (DRUG), DHA (Docosahexaenoic Acid) (DRUG).
Who is sponsoring clinical trial NCT00440050?
This trial is sponsored by Alzheimer's Disease Cooperative Study (ADCS), which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.